The group's principal activities are to develop multiple proprietary gene delivery and gene expression systems and pegylation technologies and apply our preclinical and early clinical development expertise to create novel therapeutics and improved versions of currently marketed biopharmaceuticals. The group focuses on research, preclinical and early stage clinical development of products in several therapeutic areas including cardiovascular disorders, oncology, haematology and immunology. The group has three product platforms for the development of novel therapeutics namely the gene medicine, geneswitch(R) and dna vaccine platforms. The gene medicine platform includes a comprehensive array of proprietary nucleic acid delivery systems. Geneswitch(R) platform controls erythropoietin protein production from an injected gene by orally administered drug. Synthetic vaccine delivery systems provide consistent levels of gene expression and enhance efficiency of plasmid.
